The Late Breaking Session presented data on new insights into FA disease mechanisms and positive results in an FA omaveloxolone clinical trial, a novel SCA5 screening platform to identify new drug targets & the discovery of a novel gene causing SCA50.
Related topics
| Topic | Replies | Views | Activity | |
|---|---|---|---|---|
| The US Food and Drug Administration (FDA) has given orphan drug designation to a Friedreich’s ataxia drug called omaveloxolone | 6 | 1960 | July 2, 2017 | |
| Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia | 0 | 304 | November 16, 2018 | |
| FA and Omaveloxolone | 4 | 256 | June 25, 2024 | |
| Omaveloxolone versus Sulforaphane. Anti-oxidants for treatment of ataxias | 0 | 805 | November 8, 2018 | |
| First and only FDA approved prescription medicine for Friedreichs Ataxia | 0 | 136 | March 1, 2023 |